Ei­sai shut­ters on­col­o­gy unit, cuts around 80 jobs

Days af­ter an­nounc­ing a re­or­ga­ni­za­tion plan to fo­cus on deep learn­ing and its “most im­por­tant project,” the Bio­gen-part­nered Alzheimer’s drug lecanemab, Ei­sai is shut­ter­ing its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER